BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21803182)

  • 1. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.
    Vallabhajosula S; Nikolopoulou A
    Semin Nucl Med; 2011 Sep; 41(5):324-33. PubMed ID: 21803182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.
    Rufini V; Shulkin B
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):341-50. PubMed ID: 19088689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
    Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
    Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-iodobenzylguanidine and analogues: chemistry and biology.
    Vaidyanathan G
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):351-68. PubMed ID: 19088690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
    Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
    Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
    Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of
    Das S; Sakhare N; Mathur A; Mallia MB; Mirapurkar S; Sheela M; Sarma HD; Sachdev SS; Dash A
    Nucl Med Biol; 2019; 68-69():49-57. PubMed ID: 30770228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sympathomimetic effects of MIBG: comparison with tyramine.
    Graefe KH; Bossle F; Wölfel R; Burger A; Souladaki M; Bier D; Dutschka K; Farahati J; Bönisch H
    J Nucl Med; 1999 Aug; 40(8):1342-51. PubMed ID: 10450687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
    Vaidyanathan G; Affleck DJ; Norman J; O'Dorisio S; Zalutsky MR
    Bioconjug Chem; 2007; 18(6):2122-30. PubMed ID: 17979223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
    Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
    Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.
    Taggart D; Dubois S; Matthay KK
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):403-18. PubMed ID: 19088694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.
    Smets LA; Loesberg C; Janssen M; Metwally EA; Huiskamp R
    Cancer Res; 1989 Jun; 49(11):2941-4. PubMed ID: 2720653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of specific activity on cardiac uptake of iodine-123-MIBG.
    Farahati J; Bier D; Scheubeck M; Lassmann M; Schelper LF; Grelle I; Hanscheid H; Biko J; Graefe KH; Reiners C
    J Nucl Med; 1997 Mar; 38(3):447-51. PubMed ID: 9074536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
    Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
    Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
    Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
    Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
    Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
    J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I-131-MIBG therapies.
    Vöö S; Bucerius J; Mottaghy FM
    Methods; 2011 Nov; 55(3):238-45. PubMed ID: 22056346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.
    Khan MU; Morse M; Coleman RE
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):441-54. PubMed ID: 19088697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
    Boyd M; Sorensen A; McCluskey AG; Mairs RJ
    J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
    Défachelles AS; Cougnenc O; Carpentier P
    Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.